Anixa Biosciences Inc (ANIX)
$3.48-$0.12 (-3.22%) Today
Amit Kumar - OfficerAmit Kumar - OfficerAmit Kumar - OfficerAmit Kumar - OfficerAnixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 9 | 61,633 | $189K |
| Option exercise | 2 | 12,000 | |
| Tax withholding / forfeiture | 1 | 5,428 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
25 Form 4 filings on record, the earliest from Oct 23, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Amit Kumar - Officer | Open-market purchase | Common Stock | 5,000 | $3.47 | $17K | |
| Arnold M. Baskies - Director | Option exercise | Common Stock | 6,000 | $3.13 | $19K | |
| Arnold M. Baskies - Director | Tax withholding / forfeiture | Common Stock | 5,428 | $3.46 | $19K | |
| Arnold M. Baskies - Director | Option exercise | Employee Stock Option (Right to Buy) | 6,000 | $0.00 | - | |
| Amit Kumar - Officer | Open-market purchase | Common Stock | 5,000 | $3.44 | $17K | |
| Amit Kumar - Officer | Open-market purchase | Common Stock | 3,000 | $3.73 | $11K | |
| Amit Kumar - Officer | Open-market purchase | Common Stock | 5,000 | $3.46 | $17K | |
| Lewis H. Titterton Jr. - Director | Open-market purchase | Common Stock | 12,000 | $3.47 | $42K | |
| Lewis H. Titterton Jr. - Director | Open-market purchase | Common Stock | 2,797 | $3.28 | $9K | |
| Amit Kumar - Officer | Open-market purchase | Common Stock | 5,000 | $3.04 | $15K | |
| Lewis H. Titterton Jr. - Director | Open-market purchase | Common Stock | 2,836 | $2.64 | $7K | |
| Amit Kumar - Officer | Open-market purchase | Common Stock | 21,000 | $2.50 | $53K | |
| Arnold M. Baskies - Director | Open-market purchase | Common Stock | 10,000 | $3.04 | $30K | |
| Lewis H. Titterton Jr. - Director | Grant or award | Employee Stock Option | 25,000 | $0.00 | - | |
| Amit Kumar - Officer | Grant or award | Employee Stock Option | 350,000 | $0.00 | - | |
| Emily Gottschalk - Director | Grant or award | Employee Stock Option | 25,000 | $0.00 | - | |
| Michael Catelani - Officer | Grant or award | Employee Stock Option | 175,000 | $0.00 | - | |
| Arnold M. Baskies - Director | Grant or award | Employee Stock Option | 25,000 | $0.00 | - | |
| Lewis H. Titterton Jr. - Director | Option exercise | Common Stock | 16,000 | $2.92 | $47K | |
| Lewis H. Titterton Jr. - Director | Option exercise | Employee Stock Option | 16,000 | $0.00 | - | |
| Amit Kumar - Officer | Option exercise | Employee Stock Option (Right to Buy) | 200,000 | $0.00 | - | |
| Amit Kumar - Officer | Option exercise | Common Stock | 200,000 | $2.92 | $584K | |
| Amit Kumar - Officer | Tax withholding / forfeiture | Common Stock | 169,439 | $4.06 | $688K | |
| Lewis H. Titterton Jr. - Director | Open-market purchase | Common Stock | 10,000 | $3.08 | $31K | |
| Amit Kumar - Officer | Open-market purchase | Common Stock | 5,000 | $3.16 | $16K | |
| Arnold M. Baskies - Director | Open-market purchase | Common Stock | 5,000 | $3.39 | $17K | |
| Lewis H. Titterton Jr. - Director | Open-market purchase | Common Stock | 10,000 | $3.14 | $31K | |
| Amit Kumar - Officer | Open-market purchase | Common Stock | 5,000 | $3.15 | $16K | |
| Amit Kumar - Officer | Open-market purchase | Common Stock | 10,000 | $2.85 | $29K | |
| Lewis H. Titterton Jr. - Director | Option exercise | Common Stock | 16,000 | $2.58 | $41K | |
| Lewis H. Titterton Jr. - Director | Option exercise | Employee Stock Option | 16,000 | $0.00 | - |
Anixa Biosciences Inc (ANIX) had 10 insider filings in the last 90 days, with the most recent on 2026-08-03. The full record for ANIX runs to 25 Form 4 filings, the earliest from 2024-10-23. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
9 insider purchases of ANIX were filed in the last 90 days, totaling $189K.
No insider sales of ANIX were filed in the last 90 days.
This page tracks ANIX Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add ANIX to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
